Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Palliation
•
General Radiation Oncology
What is the role of RFA for symptomatic bone metastasis?
Is there any good data comparing RFA vs RT for painful bone metastasis?
Related Questions
What is the expected timeframe for the development of radiation myelitis and therapies that have helped with neurologic symptoms?
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
Is it safe to re-irradiate non-spine bone metastases with SBRT if they received previous SBRT?
Does your choice of dose and fractionation for bone metastasis depend on the location of the metastasis in question?
Do you use a comprehensive volumetric, rather than numeric, cutoff in consideration of SRS vs WBRT for brain metastases?
Would you offer 12-16 Gy in a single fraction for a symptomatic, non-vertebral bone metastasis?
Has there been an observed interaction between ACE inhibitors and development of angioedema in a block demarcated superficial radiation therapy treatment volume (ex. lip)?
Would you offer SRS to a hippocampal metastasis in a patient with ES-SCLC treated with prior WBRT?
What is the optimal management of pain and loss of function due to pathologic compression fractures?
What normal tissue dose constraints do you use when delivering up to 3 cycles of the palliative quad shot regimen for gynecologic pelvic malignancies?